Overview

Alzheimer's disease represents a major healthcare crisis. An estimated 5.7 million Americans suffer from this disease. As the most common type of dementia, Alzheimer's disease is a neurodegenerative disease characterized by the presence of beta-amyloid and tau proteins within brain and nerve cells. This condition disproportionately impacts menopausal women to the tune of 3.2 million diagnosed with this condition. A few unmodifiable risk factors have been identified, such as aging, family history, and genetics, but we are only beginning to understand the link between different hormones and Alzheimer's, particularly in menopausal women.

Epidemiological studies highlight metabolic abnormalities as an important contributor to Alzheimer's disease. Thus, early and accurate identification of metabolic risk factors, such as insulin resistance and hormonal imbalances, may help to delay or decrease progression of Alzheimer's disease.

Doctor Trindade will discuss her unique approach, which incorporates functional medicine principles, and offer clinical pearls to address Alzheimer's disease, particularly in women. This webinar will focus on applying and interpreting treatable metabolic and hormonal abnormalities, shown in research to be contributing risk factors for the development and progression of Alzheimer's disease.

Learning Objectives

• Describe the contribution of insulin resistance and hormonal imbalance in the development and progression of Alzheimer's disease
• Review a treatment approach in patients with increased risk, or who already have, Alzheimer disease

---